Ocular Therapeutix
OCUL
Ocular Therapeutix (OCUL) earnings history
Most recent quarter
- Fiscal period
- Q1 2026
- Period end
- Mar 31, 2026
- EPS actual
- −$0.40
- EPS estimate
- −$0.31
- EPS surprise
- −27.06%
- Revenue surprise
- −15.23%
- Revenue
- $10.8M
- Revenue estimate
- $12.7M
- Reported
- May 5, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q1 2026 | May 5, 2026 | −$0.31 | −$0.40 | −27.06% | $10.8M | SEC |
| Q3 2025 | Nov 4, 2025 | −$0.37 | −$0.38 | −2.29% | $14.5M | SEC |
| Q2 2025 | Aug 5, 2025 | −$0.36 | −$0.39 | −9.34% | $13.5M | SEC |
| Q1 2025 | May 5, 2025 | −$0.29 | −$0.38 | −29.08% | $10.7M | SEC |
| Q4 2024 | Mar 3, 2025 | −$0.25 | −$0.29 | −14.22% | $17.1M | SEC |
| Q3 2024 | Nov 14, 2024 | −$0.24 | −$0.22 | +9.35% | $15.4M | SEC |
| Q2 2024 | Aug 7, 2024 | −$0.22 | −$0.26 | −17.49% | $16.4M | SEC |
| Q1 2024 | May 7, 2024 | −$0.19 | −$0.49 | −154.55% | $14.8M | SEC |
| Q4 2023 | Mar 11, 2024 | −$0.30 | −$0.35 | −18.12% | $14.8M | SEC |
| Q3 2023 | Nov 7, 2023 | −$0.29 | −$0.01 | +97.88% | $15.1M | SEC |
| Q2 2023 | Aug 7, 2023 | −$0.30 | −$0.26 | +13.74% | $15.2M | SEC |
| Q1 2023 | May 8, 2023 | −$0.26 | −$0.39 | −48.12% | $13.4M | SEC |
| Q4 2022 | Mar 6, 2023 | −$0.25 | −$0.20 | +21.04% | $14.1M | SEC |
| Q3 2022 | Nov 7, 2022 | −$0.24 | −$0.31 | −30.09% | $12.0M | — |
| Q2 2022 | Aug 8, 2022 | −$0.22 | −$0.25 | −12.61% | $12.3M | — |
| Q1 2022 | May 9, 2022 | −$0.23 | −$0.16 | +31.62% | $13.2M | — |
| Q4 2021 | Feb 28, 2022 | −$0.23 | −$0.05 | +78.63% | $12.3M | — |
| Q3 2021 | Nov 8, 2021 | −$0.26 | $0.03 | +111.54% | $12.2M | — |
| Q2 2021 | Aug 9, 2021 | −$0.21 | −$0.11 | +47.62% | $11.7M | — |
| Q1 2021 | May 5, 2021 | −$0.21 | −$0.24 | −16.11% | $7.3M | — |
Quarterly revenue
Frequently asked questions
When did Ocular Therapeutix (OCUL) last report earnings?
Ocular Therapeutix last reported on May 5, 2026, covering fiscal Q1 2026.
Did OCUL beat earnings estimates?
No. Ocular Therapeutix reported EPS of −$0.40 for Q1 2026 against a −$0.31 estimate — a 27.06% miss.
How much revenue did OCUL report last quarter?
Ocular Therapeutix reported $10.8M in revenue for Q1 2026, against a consensus estimate of $12.7M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.